Equillium, Inc. (0FY.F)
| Previous Close | 0.6075 |
| Open | 0.6285 |
| Bid | 0.5870 x 0 |
| Ask | 0.6100 x 0 |
| Day's Range | 0.6285 - 0.6285 |
| 52 Week Range | 0.6075 - 3.0400 |
| Volume | |
| Avg. Volume | 68 |
| Market Cap | 21.629M |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8600 |
| Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
LA JOLLA, Calif., March 22, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference.
- Business Wire
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
LA JOLLA, Calif., February 17, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.
- Business Wire
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
LA JOLLA, Calif., February 07, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the SVB Securities Annual Global Biopharma Conference.
